Eli Lilly Q1 2025 Earnings: Mounjaro, Zepbound Push Revenue to Record $12.7 Billion Amid Strong Pipeline Momentum

Eli Lilly and Company (NYSE: LLY) delivered a blockbuster first quarter for fiscal 2025, fueled by the surging success of its diabetes and obesity treatments—Mounjaro and Zepbound—and further bolstered by…

Continue ReadingEli Lilly Q1 2025 Earnings: Mounjaro, Zepbound Push Revenue to Record $12.7 Billion Amid Strong Pipeline Momentum